The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ruxolitinib shows improved overall response rate for patients with chronic GvHD
The Reach3 trial (NCT03112603) is a randomized, multicenter phase III trial designed to compare the efficacy and safety of ruxolitinib in patients with chronic graft-versus-host disease (cGvHD) with the best available therapy—a study overview can be found here. Ruxolitinib is a first-in-class oral inhibitor of the tyrosine kinases JAK1 and JAK2 that has been approved for the treatment of polycythemia vera and myelofibrosis in adults, and acute GvHD in adults and pediatric patients ≥ 12 years of age.1
The Reach3 trial compared ruxolitinib with standard cGVHD therapies, and topline results show that the ruxolitinib treatment arm met the primary endpoint, which was to improve the overall response rate at 24 weeks for patients with steroid-refractory or steroid-dependent cGvHD who underwent allogeneic stem cell transplantation.
The trial also met key secondary endpoints, significantly improving failure-free survival and patient-reported symptoms as measured by the modified Lee cGvHD symptom scale.
The Reach3 study builds on the results of the Reach1 and Reach2 trials, which demonstrated that ruxolitinib was effective at improving outcomes in patients with steroid-refractory acute GvHD. The results of the Reach2 trial were recently reported by the GvHD Hub.
The Reach3 trial results will form the basis of a submission to the U.S. Food and Drug Administration (FDA) for the approval of ruxolitinib in patients with steroid-refractory or steroid-dependent cGvHD.1
The complete results of the study will be presented at the 46th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, which will be held as a virtual edition on August 28–September 1, 2020.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content